Genetically Tailored Antihypertensive Therapy Shows Promise

NEW YORK (MedscapeWire) Apr 03 — Antihypertensive therapy may be tailored to specific genetic variations, according to a case-control study published in the April 3 issue of The Journal of the American Medical Association. People carrying a variant of the alpha-adducin gene, but not the wild type, had half the risk of myocardial infarction (MI) or stroke when treated with low-dose diuretics than with other antihypertensives.
"If these findings are confirmed in other studies, screening for the adducin variant could identify hypertensive patients especially likely to benefit from low-dose diuretic therapy," lead author Bruce M. Psaty, MD, PhD, from the University of Washington in Seattle, says in a news release.

לכתבה המלאה

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים